Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(12):2769-76.
doi: 10.1080/21645515.2015.1074362.

Research and development of therapeutic mAbs: An analysis based on pipeline projects

Xiaomei Geng  1 , Xiangjun Kong  1 , Hao Hu  1 , Jiayu Chen  2   3 , Fengqing Yang  4 , Hongyu Liang  1 , Xin Chen  1 , Yuanjia Hu  1
Affiliations

Research and development of therapeutic mAbs: An analysis based on pipeline projects

Xiaomei Geng et al. Hum Vaccin Immunother. 2015.

Abstract

As the subject of active research and development (R&D) in recent decades, monoclonal antibodies have emerged among the major classes of therapeutic agents for treatment of many human diseases, especially cancers, infections, and immunological disorders. This article surveys the landscape of R&D projects of therapeutic monoclonal antibodies (mAbs), which are mostly used for disease immunotherapy, from a number of perspectives, including therapeutic indications, development phases, participants, and citation of related patents. The results of this research can be used as a reference resource for pharmaceutical researchers, investors, and policymakers in the field of therapeutic mAbs.

Keywords: R&D; development trends; monoclonal antibody; patent citation network; pipeline projects; therapeutic application.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Therapeutic categories of mAbs. Category of “others” includes eye diseases, respiratory diseases, metabolic diseases, etc.
Figure 2.
Figure 2.
Immunotherapeutic patterns of anti-cancer mAbs.
Figure 3.
Figure 3.
The trend and proportion of mAbs-related R&D over time.
Figure 4.
Figure 4.
Share of mAbs-related R&D programs at different pipeline phases. The designations of the phases of the projects are based not fully on definitions by regulatory authorities but on company definitions endorsed by IMS Health.
Figure 5.
Figure 5.
The top 25 organizations involved in mAb R&D.
Figure 6.
Figure 6.
Patent citation network of mAbs. Nodes represent patents; edges represent the citation relationship between patents. Different colors indicate patents associated with different therapeutic areas. Colors corresponding to the specific therapeutic areas mentioned above, with the exception of purple nodes, which represent patents in multiple therapeutic areas.
See this image and copyright information in PMC

References

    1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7; PMID:1172191; http://dx.doi.org/ 10.1038/256495a0 - DOI - PubMed
    1. Smith SL. Ten years of Orthoclone OKT3 (muromonab-CD3): a review. J Transpl Coord 1996; 6:109-19; PMID:9188368; http://dx.doi.org/ 10.7182/prtr.1.6.3.8145l3u185493182 - DOI - PubMed
    1. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7:622-32; PMID:17641665; http://dx.doi.org/ 10.1038/nri2134 - DOI - PubMed
    1. Leavy O. Therapeutic antibodies: past, present and future. Nat Rev Immunol 2010; 10:297; PMID:20422787; http://dx.doi.org/ 10.1038/nri2763 - DOI - PubMed
    1. Niwa R, Satoh M. The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology. J Pharm Sci US 2015; 104:930-41; PMID:25583555 - PubMed

Publication types

Substances

LinkOut - more resources